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Abstract
Multiple myeloma (MM) is a hematological disease characterized by an abnormal accumulation of plasma cells in the bone
marrow. These cells have frequent cytogenetic abnormalities including translocations of the immunoglobulin heavy chain
gene and chromosomal gains and losses. In fact, a singular characteristic differentiating MM from other hematological
malignancies is the presence of a high degree of aneuploidies. As chromosomal abnormalities can be generated by
alterations in the spindle assembly checkpoint (SAC), the functionality of such checkpoint was tested in MM. When SAC
components were analyzed in MM cell lines, the RNA levels of most of them were conserved. Nevertheless, the protein
content of some key constituents was very low in several cell lines, as was the case of MAD2 or CDC20 in RPMI-8226 or
RPMI-LR5 cells. The recovery of their cellular content did not substantially affect cell growth, but improved their ability to
segregate chromosomes. Finally, SAC functionality was tested by challenging cells with agents disrupting microtubule
dynamics. Most of the cell lines analyzed exhibited functional defects in this checkpoint. Based on the data obtained,
alterations both in SAC components and their functionality have been detected in MM, pointing to this pathway as a
potential target in MM treatment.
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Introduction
Multiple myeloma (MM) is the second most frequent hemato-
logical disease affecting mainly elderly individuals. It represents
1% of all the neoplasias and 13% of the hematological
malignancies [1,2]. Recently and thanks to new therapies, an
increase of survival above 50% has been achieved. Nevertheless it
is still a non-curable disease since sooner or later relapses will
occur [3]. For that reason, important efforts are being made to
identify new therapeutic targets that can be used to treat myeloma
patients.
At the cellular level, MM is a B cell neoplasia that affects the last
stages of lymphoid differentiation. Three key features of this
disease, and critical for its diagnosis, are the accumulation of
plasma cells (PCs) in the bone marrow, the production and
secretion of immunoglobulins and cytokines, and the activation of
osteoclasts that induce bone destruction [4,5]. In addition, another
important characteristic of MM is its highly unstable genome, in
which, not only translocations, but also whole chromosome gains
and looses have been described. Thus, chromosomal gains have
been described in 30% of MM, affecting mainly odd chromosomes
and being associated to the hyperdiploid phenotype, in which
primary translocations of the immunoglobulins are infrequent
[6,7]. Besides, chromosome 13, in which the human Retinoblas-
toma gene is located, is frequently lost [8]. Moreover, the presence
of these chromosome abnormalities correlates with disease
outcome [9,10,11].
Chromosomal instability is an important characteristic not only
of MM, but also of solid tumors [12,13]. If aneuploidy is cause or
consequence of the tumoral process has long been discussed.
Nevertheless, recent reports have demonstrated that aneuploidy
generation by the manipulation of proteins involved in the mitotic
regulation, such as the components of the spindle assembly
checkpoint (SAC), is enough to induce tumor formation in animal
models [14,15,16,17]. The SAC is a highly conserved signal
transduction pathway that during mitosis controls the adequate
distribution of the genomic complement between the two daughter
cells. Thus, at the beginning of mitosis, a number of proteins will
complex together and localize to the kinetochores blocking cell
cycle progression until all the chromosomes are bipolarly attached
to the spindle microtubules [18]. Alterations in those proteins will
produce abnormal distribution of the chromosomes to the two
daughter cells and aneuploidy generation that will eventually lead
to tumor formation, as we have previously demonstrated for the
SAC proteins MAD2 and HEC1 [14,16].
From the therapeutic point of view, in the last few years several
drugs interfering with SAC function have been investigated and
some of them are already being tested in clinical trials (reviewed in
[19]). That is the case of inhibitors of Aurora kinases, Polo-like
kinases (PLK) or CENP-E. If SAC is altered in MM, it appears
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clinic. In fact, several recent reports indicate that inhibitors of the
mitotic Aurora kinases induce apoptosis in MM cells and could be
useful in MM treatment [20,21,22,23,24]. Also PLK inhibitors
could have potential anti-tumor activity in MM [25].
Given the highly unstable karyotype found in MM cells and the
lack of knowledge of the status of SAC components in this disease,
we wanted to investigate the amount and status of SAC
components in MM in order to determine if such checkpoint
could have a role in the generation of the aneuploidy observed in
this disease.
Materials and Methods
Reagents and immunochemicals
Cell culture media, sera, G418 and CellTracker
TM red
CMPTX were purchased from Invitrogen, Immobilon P mem-
branes from Millipore Corp, and nocodazole from Sigma
Chemical Co. Other generic chemicals were purchased from
Sigma Chemical Co., Roche Biochemicals or Merck.
The anti-MAD2 and anti-BUBR1 antibodies were from BD-
biosciences, the anti-CDC20, anti-BUB3 and anti-KNTC1 from
Santa Cruz Biotechnology, the anti-atubulin from Oncogene
Research Products and the anti-PTTG was a generous gift from
Dr. Pintor Toro (Andalusian Center for Molecular Biology and
Regenerative Medicine, Seville, Spain). The horseradish peroxi-
dase (HRP)-conjugated secondary antibodies were from Bio-Rad
and the fluorochrome conjugated ones from Thermo Scientific
(Pierce: Dylight).
Cell lines, cell culture and Western Blot
Multiple myeloma cell lines have previously been described: MM1S,
MM1R, MM144, RPMI-8226 U266, OPM2 and NCI-H929 [26];
RPMI-LR5, U266-DOX4 and U266-LR7 [27]. MGG and SJR were
derived in the laboratoryfrompatient samples. The use ofthose clinical
samples for investigation was approved by the Ethical Committee of
the University Hospital of Salamanca and patients gave their written
consent for that use. All those cell lines were grown in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS) and
antibiotics. Previously described 293T [26,28] and HeLa [29,30,31]
cells were grown in DMEM supplemented with 5% FBS. All the cell
lines were cultured at 37uC in a humidified atmosphere in the presence
of 5% CO2-95% air.
To prepare cells for protein analyses, they were collected and
centrifuged at 10,000 g for 2 minutes, washed in PBS and lysed in
ice-cold lysis buffer as described elsewhere [32]. Protein amount
was quantified by the Bradford assay and proteins detected by
Western blot following standard procedures. For quantitative
Western blot, fluorochrome-labeled secondary antibodies were
used and the membranes were scanned and analyzed in the
Odyssey Infrared Imaging System (Ly-cor Biosciences) using the
Odyssey 3.0.16 software.
Cell cycle synchronization and DNA analysis by flow
cytometry
In order to synchronize cells at the G2/M transition,
nocodazole treatment was performed. Cells were treated with
200 ng/ml nocodazole for 20 hours and harvested by centrifuga-
tion. For DNA analysis by flow cytometry, ethanol fixed cells were
stained with 5 mg/ml propidium iodide (PI) and 250 mg DNAse-
free RNAse. A total of 30,000 cells were acquired in the PI gate by
using a FACSCalibur flow cytometer and CELLQUEST software
(Becton Dickinson) and analyzed on MODFIT LT
TM software
(Verity software).
Transfections, generation of retroviruses and infection
Transfections and retroviral generation were done as previously
described [26], using a modified protocol. Thus 293T cells were
transfected using the JetPEI
TM reagent (Polyplus-transfection Inc,
Illkirch, France) following the manufacturers’ instructions. The
transfection mix contained DNA of the different plasmids (2.5 mg
pMDG-VSV, 5 mg pNGUL-MLV-gag-pol and, 3 mg of the
retroviral vector (empty vector or MSCV-IG-hMAD2)) and added
to the cells for 8–10 hours. 24 hours after the transfection,
medium was replaced with complete virus-collecting medium
and 8 hours later, target cells were resuspended in the virus-
containing medium including 6 mg/ml polybrene at a concentra-
tion of 500,000 cells/ml. Cells were infected three times with 10–
12 hours interval between infections.
Cell proliferation assays
The analysis of MM cell proliferation was performed using a
modified methylthiotetrazole (MTT) colorimetric assay that has been
previously described [32]. Briefly, cells were plated in triplicates and
on the day of the experiment, MTT was added to the wells at
0 . 5m g / m la n di n c u b a t e da t3 7 uC for 4 hours. The MTT formazan
crystals were then dissolved in isopropanol-HCl and the absorbance
of the samples was recorded at 570 nm using a Tecan fluorimeter
with the X-Fluor 4 software. At least three wells were analyzed for
each condition, and the results are presented as the mean +/2 SD of
a representative experiment repeated at least twice.
Table 1. Proteins of the SAC tested in MM cell lines.
GENE OLIGO SENSE OLIGO ANTISENSE
Aurora K A AACCTCTGCTTCCTGGGTTT ACGTTTTGGACCTCCAACTG
Aurora K B GGGAGAGCTGAAGATTGCTG GCACCACAGATCCACCTTCT
Aurora K C ATTTCATTGTGGCCCTGAAG ATACAGGCGCAGGATATTGG
Borealin CCTGACACCCAGGTTTGACT CACTGGCACAGTGAGGAAGA
BUB1 CCTTTGGAGAACGCTCTGTC TGTGAAGTCTCCTGGGCTCT
BUB3 GGTGGTTCTGATGGCTTTGT GCAAGCGTAGTCCCATCATT
BUBR1 AGCCAGAACAGAGGACTCCA ATCCATGGCTGGACTGTAGG
CDC20 CTACAGCCAAAAGGCCACTC CCAATCCACAAGGTTCAGGT
CENP-E GTTGATCTTGCAGGCAGTGA TGAAACCACCAACTTGTCCA
HEC1-NDC80 AGGCAAAGAAGCGATTGAAA ACCAGCCTCGGGATTAAACT
KNTC1 ATTTCTCCTCCCGTGGATCT GTTCTGTGCTGTGCCAAAGA
MAD1 CAAGGAGGTTTTCCAGACCA GCCTTGAAGATGAGGCAGTC
MAD2 GATGACAGTGCACCCAGAGA TTCCAACAGTGGCAGAAATG
MPS1-TTK1 CAGCAGCAACAGCATCAAAT TGCTTGAACCTCCACTTCCT
PLK1 GACAAGTACGGCCTTGGGTA GTGCCGTCACGCTCTATGTA
PLK2 AAAGTTGGGGACTTCGGTCT CACAGCCATGTCCTTGTTTG
PLK3 CACTTTGAGGACGCTGACAA GATCTGCCGCAGGTAGTAGC
PLK4 CCACAGACAACAATGCCAAC GGTCTGCAAATGGAAAAGGA
PTTG-Securin AAAGCTCTGTTCCTGCCTCA GAGAGGCACTCCACTCAAGG
Separase GCCCAGTTACACCTGGAAGA ACACCCTTGGTCACCTTCTG
Survivin TGGCAGCTGTACCTCAAGAA AATCAGGCTCGTTCTCGGTA
ZW10 CGCACAAAGAGGAGAAGACC CTTCAGCAGCATCTGACCAA
GAPDH TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG
A list of the SAC and kinetochore genes whose expression levels have been
determined in MM cell lines is listed. Besides, the sense or antisense
oligonucleotides used to assess such expression are shown.
doi:10.1371/journal.pone.0027583.t001
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analysis
To count anaphases and visualize their chromosomes, cells were
plated on poly-L-lysine-coated glass coverslips. 24–48 hours after
plating, cells were fixed in 2% p-formaldehyde for 30 minutes,
washed in PBS and stained with DAPI. Once mounted, anaphases
were counted and analyzed in a Zeiss Axioplan2 fluorescence
microscope and representative images acquired by confocal
immunofluorescence microscopy using an SP5 Leica apparatus
with the LAS-AF software.
For the cytogenetic analysis, MM cells were harvested after
mitotic arrest using colcemid (Invitrogen) and metaphase slides
were prepared according to standard protocols. Twenty to fifty
metaphases were analyzed for each cell line, and the karyotypes
were described according to the International Conventional
System for Human Cytogenetic Nomenclature (ISCN).
For the CGH arrays, all cell lines were analyzed using a
126135 K NimbleGen Human CGH Whole Genome v2.0 array
(Roche Diagnostics, Mannheim, Germany). This microarray
platform provides measurements from 135,000 unique genomic
loci. The hybridization, image analysis, extraction of fluorescence
intensities and their log2 ratios, together with their subsequent
normalization, were carried out following the manufacturer’s
recommendations. Gender-matched human DNA was used as
reference. Each of the two reference samples, one female and one
male, consisted of a pool of DNA from normal lymphocytes from
several healthy people (G147A-G152A; Promega, Madison, WI).
Briefly, 500 ng of tumor and reference DNA were labeled with
Cy3 and Cy5, respectively. They were combined (4 mg each) and
dried by vacuum centrifugation. The DNA was resuspended in
3.3 mL of Sample Tracking Control and vortexed; 8.7 mLo f
NimbleGen hybridization solution was added to the tube, mixed
well, and heated at 95uC for 5 min in the dark. Samples were
hybridized for 16–20 h at 42uC, then washed with NimbleGen
wash buffers and scanned at 10-mm resolution using the GenePix
4000B dual scanner (Axon Instruments, Burlingame, CA, USA).
Data were extracted from scanned images using NimbleScan
2.5 extraction software (Roche NimbleGen, Madison, WI), which
Figure 1. MM cell lines are genetically unstable and typically aneuploid. A. Representation of the karyotype obtained by CGH arrays on
genomic DNA of the indicated cell lines. The percentage of the total number of probes that are conserved, gained or lost are indicated in different
colors (shown on the right). B. Representation of the karyopype obtained with conventional metaphase chromosome counts. C. Mean chromosome
numbers as well as the mode of 50 metaphases counted in the indicated cell lines are shown. Besides, the characteristic translocation found on each
cell line is detailed in the bottom row.
doi:10.1371/journal.pone.0027583.g001
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data files. Cy3 and Cy5 images were scanned independently
through two separate channels and the quantified data were
analyzed using the Cy5/Cy3 intensity ratio converted into log2.
All the common analysis, visualization and integration steps of
array-CGH (aCGH) computational analysis were using waviCGH
software [33].
RNA purification and quantitative RT-PCR
RNA was isolated from the different cell lines as described
elsewhere, 1 mg primed with poly-T and cDNA synthesized with
M-MLV reverse transcriptase following the manufacturers’
instructions (Promega). The relative levels of gene expression of
the SAC proteins were determined by real-time quantitative
polymerase chain reaction (qRT-PCR) using the oligonucleotides
shown in table 1. The reactions were performed using iQTM
SYBR Green Supermix (Bio-Rad Laboratories, Madrid) and
recorded with the Bio-Rad iQ5 software. The relative quantitation
of the gene expression was performed through the cycle threshold
(CT) increment method [34]. The results were normalized using
GAPDH as a reference gene, and are shown in a heat map. For it,
the gplot package for R environment was used with the
‘‘Euclidean’’ method for distance calculation and the complete
linkage method for hierarchical clustering.
Results
Multiple myeloma cell lines are highly aneuploid
One of the characteristics of multiple myeloma (MM) that
distinguishes it from other hematological malignancies is the presence
of a high number of aneuploidies [5]. In order to analyze the cause of
these aneuploidies we first investigated the genetic profile present in
different MM cell lines that we had available in our laboratory by
using two different and complementary strategies: regular karyotyp-
ing and CGH arrays.The analysis of the CGHarrays confirmed that,
as expected [35], all the cell lines analyzed were genetically unstable
(Figure 1A). Thus, when all the different probes used in this approach
were taken into consideration, there was a high number of fragments
gained or lost, that was maintained between the cell lines. The
percentage of conserved probes varied between 56–65% of the total.
In that sense, the most unstable cell lines were RPMI-8226 and
MM1S, meanwhile the most conserved one was U266 (Figure 1A).
Detailed description of the chromosomes and fragments gained and
lost in the different cell lines is shown in Figures S1, S2, S3, S4.
The chromosomal counts obtained with the regular karyotyping
confirmed these data (Figures 1B and C). They also showed that
OPM2, MM1S and MM1R are mainly tetraploid and, overall, all
the MM cell lines analyzed are aneuploid with chromosomal
numbers far from the 46 normal diploid content.
Figure 2. Expression of SAC proteins in MM cell lines. Total RNA purified from the different MM cell lines as well as plasma cells (CD38pos) or
other white blood cells (CD38neg) was converted into cDNA by the reverse transcriptase reaction using oligo-dT. Quantitative PCR reaction was
performed with oligonucleotide pairs specific for the indicated proteins (indicated on the right) on the different cell lines (shown on the bottom). The
relative amount of the different proteins were normalized with the housekeeping gene GAPDH and represented in a heat map.
doi:10.1371/journal.pone.0027583.g002
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Several potential causes have been postulated in aneuploidy
generation, being one of them the alteration of the SAC. To
analyze the potential role of SAC missregulation in the generation
of the aneuploidies typical of MM, we determined the levels of
most of the proteins that participate in SAC regulation in
myeloma cell lines, as well as some other proteins constituent of
the kinetochore, and also linked to that checkpoint. For these
analyses, RNA from the different exponentially growing cell lines
was purified, and quantitative RT-PCR (qRT-PCR) performed.
The proteins whose expression has been determined as well as the
primers used in this approach are shown in table 1. A total of 23
SAC proteins were analyzed at the RNA level in twelve MM cell
lines. As control, the levels of the different proteins were analyzed
in plasma cells (CD38+) or other white blood cells (CD382)
obtained and purified from spleen. To normalize the RNA levels,
the housekeeping gene GAPDH was used (Figure 2). Overall the
levels differed from the two normal cell populations (CD38
+ and
CD38
2) used as controls, which clustered together (Figure 2).
mRNA expression was quite uniform in MM cell lines with only
some exceptions. Thus, Aurora kinase C levels were uniformly low
in most cell lines, with the exception of the SJR cell line that
showed very high levels. Similarly PLK2 or PLK3 levels were low
except in MM1S, MM1R and MM144 cells (PLK2) or RPMI-
LR5 (PLK3). Interestingly, all these proteins exhibited high levels
in the two normal populations. By contrast, the remaining SAC
proteins were highly expressed in MM cell lines, with the
exception of CDC20, PLK1 and PTTG/securin which displayed
low levels in the RPMI-LR5 cell line. Together, these results
indicate that MM cell lines expressed levels of SAC components
different to normal PCs.
Deficiency of some key SAC proteins in MM cell lines
The protein levels of some key components of the SAC were
validated by Western blot (WB) assays. Most of the SAC proteins
analyzed were expressed in the different cell lines examined
(Figure 3). Besides, as above reported for RNA levels, the protein
levels only slightly differed among the cell lines, demonstrating that
these levels are tightly controlled. We have also confirmed that
some proteins are downregulated, particularly MAD2 in RPMI-
8226 and RPMI-LR5 cells or CDC20 in the latter cell line. These
cell lines had very low levels of MAD2, but still enough to sustain
cellular proliferation. Interestingly, the absolute lack of MAD2 has
been reported to be lethal both in vivo [36] and in vitro [37].
Reconstitution of MAD2 protein in RPMI cells improves
their mitosis
Alteration of MAD2 levels induces chromosome missegregation
both in vitro and in vivo [16,36,37]. Given the low levels of this
protein in RPMI-8226 cells, chromosomes dynamics were studied.
Anaphases were counted both in RPMI-8226 and HeLa cells, an
extensively used model cell line with an adequate SAC [30,31]. In
this context, the percentage of abnormal anaphases in which
chromosomes were left behind or lost between the two daughter
cells were quantified. While HeLa anaphases were close to normal
and almost 80% of the anaphases were normal, RPMI-8226 were
not as efficient segregating their chromosomes (Figures 4A and B).
Figure 3. Protein expression of different SAC components in MM. Protein extracts from the MM cell lines indicated at the top of the figure
were prepared, quantified, and 50 mg separated by SDS-PAGE. Once transferred, membranes were proved with antibodies specifically detecting the
proteins shown on the left.
doi:10.1371/journal.pone.0027583.g003
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PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27583Figure 4. Characterization of the recovery of MAD2 levels on RPMI-8226 cells by retroviral transduction. A. RPMI-8226 cells exhibit
chromosome segregation defects. Hela or RPMI-8226 cells were plated on glass coverslips and 2 days later fixed, counterstained with DAPI and
anaphases counted at a fluorescence microscope. Yellow arrows point to chromosomal defects. B. The presence of chromosomes left behind
(delayed chromosomes) or lost between the two daughter cells was measured in at least 50 anaphases in the indicated cell lines and represented as
the percentage of cells with the different defect. C. Schematic representation of the plasmid used to transduce MM cells with hMAD2. D-F. Recovery
SAC Alterations in Multiple Myeloma
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behind at anaphase and telophase, and chromosomal bridges were
also detected (yellow arrows, Figure 4A).
We hypothesized that if those defects in chromosome dynamics
were at least partially due to the extremely low levels in MAD2 in this
cellline,the recovery in those levelsshouldimprove mitosis. To verify
this fact, the levels of MAD2 were increased in RPMI-8226 cells by
retroviral infection using the vector shown in Figure 4C. Once
transduced with this vector,MAD2 levels wereanalyzed by regular as
well as quantitative WB four days later (Figure 4D). Under those
conditions MAD2 levels in RPMI-8226 cells infected with the
retroviral construct were close to those of the MGG or MM1S cell
lines. The moderate increase in MAD2 levels in RPMI-8226 cellsdid
not affect their proliferation, as measured by MTT assay (data not
shown), although, as expected based in previous reports [16,38], it
induced a small accumulation of cells at the G2/M transition of the
cell cycle (Figure 4E), indicating a more active checkpoint.
When chromosomal dynamics were assessed in those RPMI-
MAD2 rescued cells, the distribution of chromosomes between the
two daughter cells was slightly improved (Figure 4F), and the
percentage of cells with normal mitosis increased, indicating that
the missregulation of MAD2 levels could partially cause the
genetic instability appreciated in this cell line.
Most of MM cell lines exhibit a defective SAC
The above results indicated that MAD2 could be involved in
controlling the SAC in MM. However the relatively low recovery
of SAC function upon restoration of MAD2 suggested that other
components of the SAC could be involved in controlling this
checkpoint in MM. To test this possibility, we evaluated the
functionality of the SAC on MM cell lines expressing normal levels
of MAD2. The SAC will detect if at the beginning of mitosis sister
chromatids are bipolarly attached to the microtubules of the
mitotic spindle by their kinetochores. The presence of a single
unattached kinetochore will trigger the checkpoint and block the
mitotic progression at metaphase. Thus, in the presence of
microtubule-interfering agents, if the SAC is normally functional,
cells should be arrested at the G2/M transition without
progressing further in the cell cycle. On the contrary, if they lack
such checkpoint, they will escape the block.
To clarify the functionality of the SAC in MM cells, they were
challenged with the microtubule-interfering agent nocodazole. For
these experiments, and as a well established model of an adequate
SAC, we used HeLa cells. In general, normally proliferating MM
cell lines exhibited a regular cell cycle profile, even though when
compared with HeLa cells, the percentage of cells at the different
phases of the cell cycle was shifted towards those in G0/G1
(Figure 5A, upper panels). After nocodazole treatment, the degree
of synchronization of MM cell lines was lower than in HeLa cells,
even if nocodazole treatment was extended for a longer period
(20 hours versus 16 hours for HeLa cells) (Figure 5A). Moreover,
some cell lines such as MM1S or SJR did not efficiently arrest
under these conditions. This result is important as it indicates that
these cell lines escape the SAC control. To verify if such escape
was due to a slower proliferation (cells did not reach the
checkpoint in 20 hours) or a deficient checkpoint, cells were
arrested with nocodazole for longer times and samples were
harvested every 12 hours up to 60 hours. Even in those conditions
cells did not efficiently arrest (Figure 5B). Instead, after a 36 hour
nocodazole treatment they went through cell death, similarly to
what happened to HeLa cells.
To confirm that MM cells did escape from the block, we
followed another strategy based on the use of fluorescent probes
that are retained in living cells. These reagents will be equally
distributed into the two daughter cells at cell division, getting each
one of them half of the initial markers. MM cells were labeled for
30 minutes with CellTracker Red CMPTX, prior to a 40 hour
nocodazole treatment. If cells do escape the arrest a decrease in
the staining should be detected. MM1S and SJR together with
HeLa (control) cells were investigated. HeLa cells were blocked by
nocodazole (Figure 5C, upper panel). By contrast MM1S cells
under the same conditions did not efficiently arrest in nocodazole
(Figure 5C, 2
nd panel). In fact, two subpopulations were found,
one that had normally divided and another one that had arrested
in nocodazole (Figure 5C). Regarding SJR, it showed a deficient
arrest that seem to be due to a low doubling time, as confirmed by
the fact that even in the asynchronously growing population part
of the cells had not divided after 40 hours (Figure 5C, lower
panel).
In conclusion these functional data indicate that MM cell lines
have a defective checkpoint when challenged with nocodazole.
Discussion
One of the characteristics distinguishing MM from other
hematological malignances is the presence of a highly abnormal
karyotype in which both translocations as well as partial or whole
chromosome gains or loses are detected [9,10]. Looking for the
cause of such abnormalities, the spindle checkpoint was analyzed.
Using cellular models and RNA expression analyses, the levels of
those proteins directly involved in the SAC or the kinetochore
dynamics were determined indicating that the core proteins of the
SAC or the kinetochore are regularly expressed in MM at the
transcription level. Nevertheless, some other proteins further
related to the SAC, such as the Auroras (A and C) or PLK2 or 3,
show a more variable expression. Thus, for example, the absolute
expression level of PLK3 was very low in all the MM cell lines
analyzed, except in the line SJR.
Protein levels of most of these genes were also conserved in most
of the cells lines analyzed, as demonstrated by Western blotting
assays. Nevertheless in the cell lines RPMI-8226 and RPMI-LR5,
MAD2 protein was expressed at very low levels. The fact that
RNA amount is normal but their protein content is markedly
diminished point to either translational defects or decreased
stability of this protein in those cell lines. So far, the complete lack
of MAD2 protein has been described to be lethal both in cellular
[37] and animal models [36]. Surprisingly, RPMI-8226 cells still
exhibited a robust SAC function when challenged with nocodazole
indicating that they still had a fully active checkpoint indepen-
dently of MAD2. Nevertheless in this context, the activation of the
checkpoint after interfering microtubules dynamics could be due,
not only to MAD2, but to another branch of the checkpoint. Thus,
of MAD2 levels in the MM cell line RPMI-8226. RPMI-8226 cells were transduced with the vector shown in panel C or empty vector, and 2 days later
plated for the subsequent analysis. D. Recovery of MAD2 protein levels. Protein extracts from the indicated cell lines were prepared, 30 mg separated
by SDS-PAGE and MAD2 and a-tubulin amount determined by regular WB as indicated (upper panels). Another set was similarly analyzed, but their
levels were quantified using appropriate secondary antibodies and the Odyssey software. The relative ratio of both proteins is shown in the lower
graph. E. The recovery of MAD2 levels induces a small change in their cell cycle profile, producing the accumulation of more cells in the G2/M
transition. F. Besides, a small improvement in chromosomal dynamics in mitosis is detected after MAD2 recovery, measured as described in B.
doi:10.1371/journal.pone.0027583.g004
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27583Figure 5. MM cell lines exhibit a deficient SAC when challenged with nocodazole. A. Several MM cell lines were treated with nocodazole
for 20 hours, and their cell cycle status after the arrest measured by conventional flow cytometry after DNA staining. Most of the MM cell lines
analyzed was not as efficiently arrested in those conditions as HeLa cells. B. The indicated cell lines were arrested for up to 60 hours with nocodazole
to determine if the deficient arrest was due to a slower proliferation. The increase in the time of treatment did not effectively synchronize MM1S or
SJR cells. C. Cells were labeled for 30 minutes with the CellTracker Red dye, washed out the excess and placed in culture in normal medium (green
line), or supplemented with nocodazole (pink line). Cell division in untreated cells made them loose staining, as indicated by the shift in the peak.
When the arrest was efficient, the population did not shift (see HeLa cells). Nevertheless, part of the nocodazole treated MM1S population shifted as
the control confirming that those cells had, in fact, divided even in the presence of nocodazole. On the other hand the low synchronization detected
in SJR was mainly due to the low proliferation of this cell line given that even the normal population had not divided in 40 hours.
doi:10.1371/journal.pone.0027583.g005
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MAD2 unrelated protein could replace it in the SAC function in
RPMI-8226 cells. Identifying it will help us assign new checkpoint
roles in MM. If this is a general mechanism or only applies to MM
must also be determined. For example, in the case of BUB1-
deficient mouse embryonic fibroblasts, a different response to
agents targeting microtubules dynamics has been described [39]:
their response to nocodazole is the expected G2/M arrest (causes
loss of kinetochore-spindle attachment and tension), but the effect
of taxanes is impaired (disrupts tension forces between kineto-
chores leaving attachment intact). The results that we obtained
with nocodazole indicate that MM cells may be resistant to
therapies that alter microtubule dynamics, and this is in clear
contrast to the efficacy of such therapies in several solid tumors.
Another interesting issue to be investigated is the cause of the
defective checkpoint response in MM1S cells. Since all the
components of the SAC that we investigated are present, the
cellular localization of the whole checkpoint machinery or the
presence of mutations in their sequence should be explored. So far,
several point mutations in the checkpoint components have been
described in solid tumors, some of them affecting the kinases
BUB1 and BUBR1. Interestingly, preliminary data from our
laboratory (data not shown) demonstrated the presence of several
mutations in the kinase BUBR1 in MM1S cells. Some of them,
leading to aminoacid change (M40T, Q349R, V618A), have
previously been described in solid tumors, such as colorectal
cancer, hepatocellular carcinoma or breast cancer, in which they
could have a role in impaired checkpoint function [40]. In fact one
of them (M40T) affects the KEN domain, a domain responsible for
substrate recognition and binding to CDC20 and Blinkin. The
potential role of these mutations on BUBR1 functionality as well
as the SAC itself must be carefully examined.
MM cells exhibit defects in the SAC either in terms of their
components content or its functionality, and therefore it could be
used as a target for the development of new therapies for MM. On
the other hand, targeted therapies are being developed directed
not only to the ‘‘core’’ components but also to other proteins
participating in the SAC. Thus, inhibitors of several kinases
participating in that checkpoint are under development, and some
of them are able to induce apoptosis in MM cells as is the case of
Aurora kinase [21,22,23,24,41] and PLK inhibitors [25]. More-
over, there is a phase II clinical trial recruiting MM patients to be
treated with the aurora kinase inhibitor MLN-8237. If the
inhibition of other components of the SAC could similarly affect
their function, new lines of research could be opened leading to the
identification of novel therapeutic targets in the MM field.
Supporting Information
Figure S1 Detailed analysis of chromosomes 1–5 by
CGH array in the indicated cell lines. Fragments of the
different chromosomes that are gained (right, green) or lost (left,
red) are indicated for the different MM cell lines (top of each
chromosome). The corresponding chromosome is indicated at the
bottom of each panel.
(TIF)
Figure S2 Detailed analysis of chromosomes 6–11 by
CGH array in the indicated cell lines. Chromosomes and
fragments were analyzed and represented as in figure S1.
(TIF)
Figure S3 Detailed analysis of chromosomes 12–17 by
CGH array in the indicated cell line. Chromosomes and
fragments were analyzed and represented as in figure S1.
(TIF)
Figure S4 Detailed analysis of chromosomes 18–22 by
CGH array in the indicated cell lines. Chromosomes and
fragments were analyzed and represented as in figure S1.
(TIF)
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